Loading...
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer....
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5584919/ https://ncbi.nlm.nih.gov/pubmed/28894382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S139520 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|